Company: INKT
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061041
Chunk: 30

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 30
---
 subject to continued employment. (7) Represents an option to purchase shares of our common stock, which vested as to one-third (1/3) of the underlying shares on January 16, 2025 and vests as to the remaining two-thirds (2/3) of the underlying shares in eight equal quarterly installments thereafter, generally subject to continued employment or service.

<div align='center'>20</div>

EQUITY PLANS Securities Authorized For Issuance Under Equity Compensation Plans The following table provides information about the securities authorized for issuance under our equity compensation plans as of December 31, 2024.

| Plan Category                          |     | Number of Securities to be 
 Issued Upon Exercise of    
 Outstanding Options,       
 Warrants and Rights(1)     
 (a)                        |         |     | Weighted Average     
 Exercise Price of    
 Outstanding Options, 
 Warrants and Rights  
 (b)                  |       |     | Number of Securities      
 Remaining Available for   
 Future Issuance under     
 Equity Compensation Plans 
 (Excluding Securities     
 Reflected in Column (a))  
 (c)                       |         |     |    |
|:---------------------------------------|:----|:---------------------------|--------:|:----|:---------------------|------:|:----|:--------------------------|--------:|:----|---:|
| Equity compensation plans approved     
 by security holders                    |     |                            | 975,648 |     | $                    | 17.70 |     |                           | 563,165 |     | -2 |
| Equity compensation plans not approved 
 by security holders                    |     |                            |       — |     | $                    |     — |     |                           |       — |     |    |
| Total                                  |     |                            | 975,648 |     |                      |       |     |                           | 563,165 |     |    |

(1) Includes shares subject to awards under our 2018 Plan and the 2021 Plan. (2) Includes shares that may be issued under the 2021 Plan and our 2021 Employee Stock Purchase Plan.

<div align='center'>21</div>

DIRECTOR COMPENSATION The following table sets forth the compensation awarded to, earned by or paid to our non-employee directors for services to us for the fiscal year ended December 31, 2024. Any compensation Dr. Buell received for 2024 in respect of her services provided to us as our President and Chief Executive Officer is